Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

latrepirdine

Known as: 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)-ethyl)-1H-pyrid(4,3b)indole, dimebone, Dimebon 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Indoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015
ABSTRACT Introduction: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive… Expand
Highly Cited
2013
Highly Cited
2013
Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model
Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
Mitochondrial Dysfunction—A Pharmacological Target in Alzheimer's Disease
Increasing evidences suggest that mitochondrial dysfunction plays an important role in the pathogenesis of neurodegenerative… Expand
  • figure 1
  • figure 2
  • figure 3
Review
2010
Review
2010
Mitochondria: a therapeutic target in neurodegeneration.
Mitochondrial dysfunction has long been associated with neurodegenerative disease. Therefore, mitochondrial protective agents… Expand
  • figure 1
  • figure 2
Review
2009
Review
2009
Mitochondrial structural and functional dynamics in Huntington's disease
Huntington's disease (HD) is an autosomal, dominantly inherited neurodegenerative disorder, characterized by chorea, involuntary… Expand
Review
2009
Review
2009
Drug development for Alzheimer's disease: where are we now and where are we headed?
  • M. Sabbagh
  • The American journal of geriatric pharmacotherapy
  • 2009
    • Corpus ID: 21405270
OBJECTIVE The aim of this article was to provide a survey of the clinical development of pharmacotherapy for Alzheimer's disease… Expand
Highly Cited
2008
Highly Cited
2008
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
BACKGROUND Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Highly Cited
2004
Highly Cited
2004
Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons
Dimebon in low concentrations potentiated activity of AMPA-receptors in rat cerebellar Purkinje neurons, while memantine produced… Expand
  • figure 1
Highly Cited
2003
Highly Cited
2003
Mitochondria as a Target for Neurotoxins and Neuroprotective Agents
Abstract: Mitochondrial permeability transition pores represent a multiprotein complex that includes components of both inner and… Expand
Highly Cited
2001
Highly Cited
2001
Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer
Abstract: Dimebon, launched earlier in Russia as an antihistamine drug, was evaluated as a representative of a new generation of… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE